Image source: Getty Images.
Raise your hand if you think big pharma Allergan‘s (NYSE: AGN)’s recent stock performance has been dismal. (Every hand raised? I thought so.) The company’s stock has dropped 24% this year, while the S&P has gained 4.2%. And that’s despite the fact that the company has beaten profit estimates in 10 out of the past 12 quarters, in addition to posting decent earnings last quarter.